Elanco Animal Health (NYSE:ELAN) Upgraded at Barclays

Barclays upgraded shares of Elanco Animal Health (NYSE:ELAN) to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.

A number of other research firms also recently weighed in on ELAN. KeyCorp assumed coverage on shares of Elanco Animal Health in a research note on Friday, November 21st. They issued an “overweight” rating and a $27.00 price target on the stock. UBS Group upped their target price on Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Wednesday, November 19th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Finally, JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $18.00 to $24.00 in a report on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $22.78.

Elanco Animal Health Price Performance

Shares of ELAN opened at $21.28 on Monday. The business’s 50-day moving average is $21.70 and its 200-day moving average is $17.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. The company has a market capitalization of $10.57 billion, a price-to-earnings ratio of 354.78, a P/E/G ratio of 2.77 and a beta of 1.86. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $23.70.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Equities research analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELAN. Primecap Management Co. CA lifted its stake in shares of Elanco Animal Health by 3.1% in the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after buying an additional 1,543,279 shares during the last quarter. Vanguard Group Inc. raised its holdings in Elanco Animal Health by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock worth $978,536,000 after acquiring an additional 759,623 shares during the period. Dimensional Fund Advisors LP lifted its position in Elanco Animal Health by 8.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock worth $497,610,000 after acquiring an additional 1,962,276 shares during the last quarter. UBS Group AG lifted its position in Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after acquiring an additional 5,961,457 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in Elanco Animal Health by 1.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company’s stock valued at $167,826,000 after acquiring an additional 292,655 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.